schneider said that he is "not aware of any relevant risk of the drug" and that his team has "not observed side effects in thousands of treated animals.".
.
.
advertisement
.
mail this article
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention....
the family of an elderly woman found dead on the floor of a hospital ward have said staff at altnagelvin denied her her dignity and prevented them from saying a final goodbye..